ValnevaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Valneva (VALN) reported revenue of $38.00M in Q2 2026.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
ValnevaTravel and endemic vaccines. IXIARO is the cash cow (€98.4M in 2025). IXCHIQ lost the US license in August 2025; BLA and IND withdrawn January 2026. Lyme candidate VLA15 is partnered with Pfizer.
Valneva (VALN) is a Biotechnology company. Travel and endemic vaccines. IXIARO is the cash cow (€98.4M in 2025). IXCHIQ lost the US license in August 2025; BLA and IND withdrawn January 2026. Lyme candidate VLA15 is partnered with Pfizer. It was founded in 2013, is headquartered in Saint-Herblain, France and employs about 700 people.
Track Valneva's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Valneva in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Valneva, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.